Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
Zai Lab has secured exclusive rights to develop and commercialize KarXT (xanomeline-trospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The agreement entails an upfront payment of $35 million to Karuna Therapeutics and potential milestone payments up to $152 million. Zai Lab will undertake the development and commercialization efforts, with tiered royalties on net sales. KarXT targets psychiatric conditions, showing promising results in late-stage trials for schizophrenia and Alzheimer's-related psychosis.
PureTech Health reported as of September 30, 2021, PureTech Level Cash and Cash Equivalents of $387.3 million and Consolidated Cash of $441.0 million. The company has raised $1.6 billion since July 2018, with 96% from third-party investors. Executives will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2021, at 7:20 AM EST. A webcast will be available online.
PureTech Health announces a groundbreaking paper published in Nature’s Scientific Reports detailing the development of the first superabsorbent hydrogel technology from naturally derived materials.
This innovation is aimed at addressing obesity and gut-related conditions by mimicking the properties of raw vegetables. The research shows that these hydrogels protect gut tissue from toxins in ex-vivo models. Their product, Plenity, is FDA-cleared and assists in weight management, with future product candidates poised to target various indications.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary for its Founded Entity, Vedanta Biosciences. Dr. Levi brings over 25 years of legal experience within the life sciences sector, having previously served at Cell Signaling Technology and Biogen. Her expertise in intellectual property, corporate governance, and complex transactions is expected to support Vedanta's goal of developing new oral therapies based on bacterial consortia.
Vedanta Biosciences has appointed Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary. With over 25 years of legal experience in the life sciences sector, including roles at Biogen and Cell Signaling Technology, Dr. Levi is expected to enhance Vedanta's legal framework as it develops oral therapies targeting the microbiome. Her appointment aligns with Vedanta's vision to innovate in drug delivery systems. The company holds over 40 patents and is recognized for its extensive library of beneficial bacteria.
PureTech Health (LSE:PRTC, Nasdaq:PRTC) announced that its founded entity, Vedanta Biosciences, achieved significant results in its Phase 2 trial of VE303 for preventing recurrent C. difficile infections. The trial demonstrated a 31.7% absolute risk reduction in recurrence rates compared to placebo, achieving primary endpoints. Following these results, the Biomedical Advanced Research and Development Authority (BARDA) exercised a $23.8 million option to support a Phase 3 trial of VE303, set to begin in 2022.
Vedanta Biosciences announced successful Phase 2 trial results for VE303, an oral treatment aimed at preventing recurrent C. difficile infections. The trial showed a 31.7% absolute risk reduction in recurrence at 8 weeks compared to placebo, translating to over 80% reduced odds of recurrence. Following these results, BARDA has exercised a $23.8 million funding option to support a Phase 3 trial set to begin in 2022. The study included 79 high-risk patients, reinforcing VE303's role in restoring gut microbiome health while addressing challenges faced by current treatments.
PureTech Health's Founded Entity, Akili Interactive, has announced successful topline results from a Phase 2 study of SDT-001, a digital therapeutic for children with ADHD, conducted in Japan. The study demonstrated significant improvements in inattention symptoms, paralleling prior studies of AKL-T01. Shionogi, Akili's partner, will consult with Japan’s PMDA for a Phase 3 study. This milestone marks Akili's first clinical trial outside the U.S., with the treatment being well-received and showing no serious adverse effects, which bodes well for the digital medicine's future in Japan.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) announced a groundbreaking study in Nature Metabolism indicating that dysfunction in mesenteric lymphatics contributes to obesity and insulin resistance. Using its Glyph™ technology, the company demonstrated that a COX-2 inhibitor can reverse these conditions in preclinical models, normalizing lymphatic function and blocking weight gain. The study's findings highlight the potential of Glyph for targeted delivery of therapeutics, marking a significant advancement in metabolic disease treatment.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced that CFO George Farmer, Ph.D., will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021, at 4:35 PM EDT. The presentation will be accessible via a webcast on the company's investor relations site. PureTech is a clinical-stage biotherapeutics firm focused on developing innovative treatments for serious diseases, operating a robust pipeline of 25 therapeutic candidates, including two with FDA and European approvals.